Victory Capital Management
DNA icon

Victory Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Victory Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-179,570
Closed -$1.46M – 2490
2024
Q3 		$1.46M Buy
179,570
+175,040
+3,864% +$1.75M ﹤0.01% 1606
2024
Q2 		$60.6K Buy
4,530
+110
+2% +$3.28K ﹤0.01% 2347
2024
Q1 		$205K Sell
4,420
-34
-0.8% -$1.76K ﹤0.01% 2217
2023
Q4 		$301K Buy
4,454
+979
+28% +$59.9K ﹤0.01% 2125
2023
Q3 		$252K Buy
3,475
+47
+1% +$3.76K ﹤0.01% 2161
2023
Q2 		$255K Buy
3,428
+620
+22% +$36.7K ﹤0.01% 2146
2023
Q1 		$149K Buy
2,808
+79
+3% +$5.01K ﹤0.01% 2301
2022
Q4 		$184K Buy
2,729
+513
+23% +$47.2K ﹤0.01% 2282
2022
Q3 		$277K Sell
2,216
-1,761
-44% -$210K ﹤0.01% 2275
2022
Q2 		$379K Sell
3,977
-18
-0.5% -$2.19K ﹤0.01% 2166
2022
Q1 		$463K Sell
3,995
-4,476
-53% -$871K ﹤0.01% 2150
2021
Q4 		$2.82M Buy
+8,471
New +$4.02M ﹤0.01% 1455

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Victory Capital Management's DNA Position: Q4 2024 in Review

Victory Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 179,570 shares — an estimated $1.46M sold.

Victory Capital Management first reported a position in DNA in Q4 2021 and held it in 12 quarters. The position peaked at $2.82M in Q4 2021. 166 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • Victory Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • Victory Capital Management sold 179,570 Ginkgo Bioworks shares in Q4 2024, an estimated $1.46M.
  • Victory Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 12 quarters.
  • Victory Capital Management's Ginkgo Bioworks position peaked at $2.82M in Q4 2021.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Victory Capital Management's 13F filing for Q4 2024, filed 6 Feb 2025.